Ortoncelli M - Search Results

1

Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients.

Mastorino L, Castelli F, Stroppiana E, Verrone A, Ortoncelli M, Susca S, Boskovic S, Passerini SG, Macagno N, Cariti C, Licciardello M, Solaroli C, Pertusi G, Aragone MG, Baggini G, Addese C, Leporati C, Peila R, Giura MT, Rossotto G, Pella P, Mocci L, Merlo G, Tiberio R, Graziola F, Quaglino P, Dapavo P, Ribero S. Mastorino L, et al. Among authors: ortoncelli m. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e838-e841. doi: 10.1111/jdv.18314. Epub 2022 Jun 22. J Eur Acad Dermatol Venereol. 2022. PMID: 35686942 No abstract available.

2

Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.

Solitano V, Facheris P, Petersen M, D'Amico F, Ortoncelli M, Aletaha D, Olivera PA, Bieber T, Ramiro S, Ghosh S, D'Agostino MA, Siegmund B, Chary-Valckenaere I, Hart A, Dagna L, Magro F, Felten R, Kotze PG, Jairath V, Costanzo A, Kristensen LE, Biroulet LP, Danese S. Solitano V, et al. Among authors: ortoncelli m. Autoimmun Rev. 2024 Mar;23(3):103504. doi: 10.1016/j.autrev.2023.103504. Epub 2023 Dec 20. Autoimmun Rev. 2024. PMID: 38128748

3

Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients.

Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Leporati C, Ortoncelli M, Bernengo MG. Osella-Abate S, et al. Among authors: ortoncelli m. Br J Cancer. 2003 Oct 20;89(8):1457-62. doi: 10.1038/sj.bjc.6601197. Br J Cancer. 2003. PMID: 14562017 Free PMC article. Clinical Trial.

4

Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study.

Savoia P, Ortoncelli M, Quaglino P, Bernengo MG. Savoia P, et al. Among authors: ortoncelli m. Dermatol Surg. 2006 Aug;32(8):1097-102. doi: 10.1111/j.1524-4725.2006.32236.x. Dermatol Surg. 2006. PMID: 16918576 No abstract available.

5

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, Fierro MT. Bernengo MG, et al. Among authors: ortoncelli m. Haematologica. 2007 Jun;92(6):784-94. doi: 10.3324/haematol.11127. Haematologica. 2007. PMID: 17550851 Free article. Clinical Trial.

6

Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma.

Fierro MT, Novelli M, Quaglino P, Comessatti A, Fava P, Ortoncelli M, Ponti R, Bernengo MG. Fierro MT, et al. Among authors: ortoncelli m. Dermatology. 2008;216(3):213-21. doi: 10.1159/000112928. Epub 2008 Jan 9. Dermatology. 2008. PMID: 18182812

7

Circulating CD4+CD25 bright FOXP3+ T cells are up-regulated by biological therapies and correlate with the clinical response in psoriasis patients.

Quaglino P, Ortoncelli M, Comessatti A, Ponti R, Novelli M, Bergallo M, Costa C, Cicchelli S, Savoia P, Bernengo MG. Quaglino P, et al. Among authors: ortoncelli m. Dermatology. 2009;219(3):250-8. doi: 10.1159/000238305. Epub 2009 Sep 11. Dermatology. 2009. PMID: 19752528

8

Adult-onset cutaneous mastocytosis in monozygotic twins.

Quaglino P, Mola F, Peroni A, Ortoncelli M, Di Bello C, Savoia P, Bernengo MG. Quaglino P, et al. Among authors: ortoncelli m. J Am Acad Dermatol. 2011 Sep;65(3):680-681. doi: 10.1016/j.jaad.2010.07.018. J Am Acad Dermatol. 2011. PMID: 21839339 Free article. No abstract available.

9

Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.

Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group. Gisondi P, et al. J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e30-41. doi: 10.1111/j.1468-3083.2012.04450.x. Epub 2012 Feb 7. J Eur Acad Dermatol Venereol. 2013. PMID: 22313340

10

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.

Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L; Psocare Study Group. Piaserico S, et al. J Am Acad Dermatol. 2014 Feb;70(2):257-62.e3. doi: 10.1016/j.jaad.2013.10.019. Epub 2013 Dec 16. J Am Acad Dermatol. 2014. PMID: 24355410 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page